<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0" xmlns:atom="http://www.w3.org/2005/Atom">
<channel>
<title>Banco Santander, S.a. — News on 6ix</title>
<link>https://6ix.com/company/banco-santander-sa</link>
<description>Latest news and press releases for Banco Santander, S.a. on 6ix.</description>
<language>en-us</language>
<lastBuildDate>Tue, 28 Apr 2026 12:00:00 GMT</lastBuildDate>
<generator>6ix RSS</generator>
<atom:link href="https://6ix.com/rss/company/banco-santander-sa" rel="self" type="application/rss+xml" />
<image>
<url>https://6ix-events-pro.s3.amazonaws.com/6ixvideo/logos/org-logo69d91376d20c3ebdd60e75b2.webp</url>
<title>Banco Santander, S.a.</title>
<link>https://6ix.com/company/banco-santander-sa</link>
</image>
<item>
<title>SunPower Closes $41 Million Funding Round $40 Million Debt Reduction</title>
<link>https://6ix.com/company/banco-santander-sa/news/sunpower-closes-dollar41-million-funding-round-dollar40-million-debt-reduction</link>
<guid isPermaLink="true">https://6ix.com/company/banco-santander-sa/news/sunpower-closes-dollar41-million-funding-round-dollar40-million-debt-reduction</guid>
<pubDate>Tue, 28 Apr 2026 12:00:00 GMT</pubDate>
<description>OREM, Utah, April 28, 2026 (GLOBE NEWSWIRE) -- SunPower Inc. (herein “SunPower,” the “Company,” or Nasdaq: “SPWR”), a solar technology, services, and installation company, today announced it had closed a private placement of $41 million in senior, convertible debenture notes with a 10% coupon (the “new offering”). The proceeds will provide liquidity and debt reduction by paying off $28.75 million of existing debt. In addition, certain investors in our prior 7.0% convertible notes have agreed to</description>
</item>
<item>
<title>Americans Determined to Grow Savings with Tax Refunds, Santander Bank Survey Finds</title>
<link>https://6ix.com/company/banco-santander-sa/news/americans-determined-to-grow-savings-with-tax-refunds-santander-bank-survey-finds</link>
<guid isPermaLink="true">https://6ix.com/company/banco-santander-sa/news/americans-determined-to-grow-savings-with-tax-refunds-santander-bank-survey-finds</guid>
<pubDate>Wed, 15 Apr 2026 14:23:00 GMT</pubDate>
<description>BOSTON, April 15, 2026--Santander Bank, N.A. ("Santander Bank") today announced findings from a new survey revealing consumers added to their savings more frequently in Q4 2025 compared to Q4 2024 and are now determined to grow their savings in 2026—with tax refunds expected to have a key role in building momentum.</description>
</item>
<item>
<title>Decision to Issue Construction Permits for Seabridge Gold's KSM Mitchell Treaty Tunnels Delayed</title>
<link>https://6ix.com/company/banco-santander-sa/news/decision-to-issue-construction-permits-for-seabridge-golds-ksm-mitchell-treaty-tunnels-delayed-2</link>
<guid isPermaLink="true">https://6ix.com/company/banco-santander-sa/news/decision-to-issue-construction-permits-for-seabridge-golds-ksm-mitchell-treaty-tunnels-delayed-2</guid>
<pubDate>Fri, 10 Apr 2026 10:00:00 GMT</pubDate>
<description>Toronto, Ontario--(Newsfile Corp. - April 10, 2026) - Seabridge Gold Inc. (TSX: SEA) (NYSE: SA) ("Seabridge" or the "Company") announces today that it has received a letter from the Ministry of Mining and Critical Minerals of British Columbia (the "Ministry") advising that a decision to issue permit amendments for construction and operation of the Mitchell Treaty Tunnels ("MTT") over their full length (the "MTT Authorization") has been delayed. The MTT are an important infrastructure component..</description>
</item>
<item>
<title>Webster Financial Corporation Announces Q1 2026 Earnings Release</title>
<link>https://6ix.com/company/banco-santander-sa/news/webster-financial-corporation-announces-q1-2026-earnings-release-1</link>
<guid isPermaLink="true">https://6ix.com/company/banco-santander-sa/news/webster-financial-corporation-announces-q1-2026-earnings-release-1</guid>
<pubDate>Thu, 09 Apr 2026 20:15:00 GMT</pubDate>
<description>STAMFORD, Conn., April 09, 2026--Webster Financial Corporation (NYSE: WBS, "the company"), the holding company for Webster Bank, N.A., today announced it will release its first quarter 2026 earnings after the close of U.S. markets on April 28, 2026.</description>
</item>
<item>
<title>Sanofi becomes market authorization holder for Nuvaxovid® in Canada, expanding COVID-19 vaccine choices for Canadians</title>
<link>https://6ix.com/company/banco-santander-sa/news/sanofi-becomes-market-authorization-holder-for-nuvaxovidr-in-canada-expanding-covid-19-vaccine-choices-for-canadians-2</link>
<guid isPermaLink="true">https://6ix.com/company/banco-santander-sa/news/sanofi-becomes-market-authorization-holder-for-nuvaxovidr-in-canada-expanding-covid-19-vaccine-choices-for-canadians-2</guid>
<pubDate>Thu, 09 Apr 2026 14:00:00 GMT</pubDate>
<description>Sanofi today announces it has become the market authorization holder in Canada for Nuvaxovid, a non-mRNA protein-based COVID-19 vaccine. Nuvaxovid represents another step in Sanofi's commitment to building a diverse portfolio of best-in-class vaccines and addressing respiratory diseases for Canadians across their lifespan. Sanofi will make Nuvaxovid available in Canada for the fall 2026-2027 season.</description>
</item>
<item>
<title>Press Release: Sanofi’s lunsekimig met primary and key secondary endpoints in phase 2 respiratory studies in asthma and CRSwNP</title>
<link>https://6ix.com/company/banco-santander-sa/news/press-release-sanofis-lunsekimig-met-primary-and-key-secondary-endpoints-in-phase-2-respiratory-studies-in-asthma-and-crswnp-2</link>
<guid isPermaLink="true">https://6ix.com/company/banco-santander-sa/news/press-release-sanofis-lunsekimig-met-primary-and-key-secondary-endpoints-in-phase-2-respiratory-studies-in-asthma-and-crswnp-2</guid>
<pubDate>Tue, 07 Apr 2026 05:00:00 GMT</pubDate>
<description>Sanofi’s lunsekimig met primary and key secondary endpoints in phase 2 respiratory studies in asthma and CRSwNP The AIRCULES phase 2b study achieved its primary and key secondary endpoints in moderate-to-severe asthma regardless of biomarker status The DUET phase 2a study met its primary and key secondary endpoints in chronic rhinosinusitis with nasal polyps, reinforcing lunsekimig’s potential as a respiratory treatmentThe exploratory VELVET phase 2b study did not meet its primary endpoint in mo</description>
</item>
<item>
<title>Madison Air Launches Roadshow for Proposed Initial Public Offering</title>
<link>https://6ix.com/company/banco-santander-sa/news/madison-air-launches-roadshow-for-proposed-initial-public-offering-1</link>
<guid isPermaLink="true">https://6ix.com/company/banco-santander-sa/news/madison-air-launches-roadshow-for-proposed-initial-public-offering-1</guid>
<pubDate>Mon, 06 Apr 2026 13:12:00 GMT</pubDate>
<description>Madison Air today announced the launch of the roadshow for its proposed initial public offering of 82,692,308 shares of common stock. The initial public offering price is currently expected to be between $25.00 and $27.00 per share. Madison Air intends to list its shares on the New York Stock Exchange under the ticker symbol "MAIR".</description>
</item>
<item>
<title>Seabridge Gold Provides Updated Mineral Resource Estimates for KSM Project</title>
<link>https://6ix.com/company/banco-santander-sa/news/seabridge-gold-provides-updated-mineral-resource-estimates-for-ksm-project-2</link>
<guid isPermaLink="true">https://6ix.com/company/banco-santander-sa/news/seabridge-gold-provides-updated-mineral-resource-estimates-for-ksm-project-2</guid>
<pubDate>Tue, 31 Mar 2026 11:30:00 GMT</pubDate>
<description>Toronto, Ontario--(Newsfile Corp. - March 31, 2026) - Seabridge Gold Inc. (TSX: SEA) (NYSE: SA) ("Seabridge") announced today updated Mineral Resource Estimates for its KSM Project located in northwestern British Columbia using metal prices of US$2,000/oz Au, US$4.00/lb Cu, US$25/oz Ag, and US$ 22/lb Mo at a currency exchange rate of 0.746 US$ per 1.00 Cdn$. For the past 10 years, KSM resource disclosure used metal prices of US$1,300/oz Au, US$3.00/lb Cu, US$20/oz Ag, US$9.70/lb Mo at a currency</description>
</item>
<item>
<title>Press Release: Sanofi’s Rezurock approved in the EU to treat chronic graft-vs-host disease</title>
<link>https://6ix.com/company/banco-santander-sa/news/press-release-sanofis-rezurock-approved-in-the-eu-to-treat-chronic-graft-vs-host-disease-1</link>
<guid isPermaLink="true">https://6ix.com/company/banco-santander-sa/news/press-release-sanofis-rezurock-approved-in-the-eu-to-treat-chronic-graft-vs-host-disease-1</guid>
<pubDate>Tue, 31 Mar 2026 05:00:00 GMT</pubDate>
<description>Sanofi’s Rezurock approved in the EU to treat chronic graft-vs-host disease Rezurock is now approved in the EU for adults and children aged 12 years and older with chronic GVHD, providing a new medicine for patients with limited treatment options Paris, March 31, 2026. The European Commission has granted a conditional marketing authorisation for Rezurock (belumosudil) for the treatment of chronic graft-versus-host disease (GVHD) in adults and in children aged 12 years and older with a body weigh</description>
</item>
<item>
<title>Press Release: AAD: new results from Sanofi's amlitelimab phase 3 studies in atopic dermatitis presented in late-breaking research session</title>
<link>https://6ix.com/company/banco-santander-sa/news/press-release-aad-new-results-from-sanofis-amlitelimab-phase-3-studies-in-atopic-dermatitis-presented-in-late-breaking-research-session-1</link>
<guid isPermaLink="true">https://6ix.com/company/banco-santander-sa/news/press-release-aad-new-results-from-sanofis-amlitelimab-phase-3-studies-in-atopic-dermatitis-presented-in-late-breaking-research-session-1</guid>
<pubDate>Sat, 28 Mar 2026 15:00:00 GMT</pubDate>
<description>AAD: new results from Sanofi's amlitelimab phase 3 studies in atopic dermatitis presented in late-breaking research session Across the COAST 1, COAST 2, and SHORE phase 3 studies, amlitelimab, dosed either Q4W or Q12W, showed progressively increasing efficacy, with no evidence of plateau at Week 24 across endpointsData reinforce potential for Q12W dosing from the start Paris, March 28, 2026. Positive results from three phase 3 studies of amlitelimab, a fully human non-T cell depleting monoclonal</description>
</item>
<item>
<title>Press Release: Sanofi’s Sarclisa subcutaneous formulation administered via on-body injector recommended for EU approval by the CHMP to treat multiple myeloma</title>
<link>https://6ix.com/company/banco-santander-sa/news/press-release-sanofis-sarclisa-subcutaneous-formulation-administered-via-on-body-injector-recommended-for-eu-approval-by-the-chmp-to-treat-multiple-myeloma-1</link>
<guid isPermaLink="true">https://6ix.com/company/banco-santander-sa/news/press-release-sanofis-sarclisa-subcutaneous-formulation-administered-via-on-body-injector-recommended-for-eu-approval-by-the-chmp-to-treat-multiple-myeloma-1</guid>
<pubDate>Fri, 27 Mar 2026 12:00:00 GMT</pubDate>
<description>Sanofi’s Sarclisa subcutaneous formulation administered via on-body injector recommended for EU approval by the CHMP to treat multiple myeloma Recommendation based on positive results demonstrating comparable efficacy, pharmacokinetics, and safety of Sarclisa regimens administered subcutaneously compared to intravenous infusionIf approved, Sarclisa subcutaneous (SC) would be the first available anticancer treatment to be administered through an on-body injector (OBI), and the first multiple myel</description>
</item>
<item>
<title>Linea Energy Closes Project Debt Financing for Watertown Solar in Michigan</title>
<link>https://6ix.com/company/banco-santander-sa/news/linea-energy-closes-project-debt-financing-for-watertown-solar-in-michigan</link>
<guid isPermaLink="true">https://6ix.com/company/banco-santander-sa/news/linea-energy-closes-project-debt-financing-for-watertown-solar-in-michigan</guid>
<pubDate>Tue, 24 Mar 2026 17:31:00 GMT</pubDate>
<description>Linea Energy ("Linea"), a U.S. based renewable energy developer and independent power producer ("IPP"), that is sponsored by EnCap Investments L.P. ("EnCap"), announced today that it has closed project financing for its Watertown solar project ("Watertown"). Watertown is a 172 MWdc utility-scale solar energy facility located in Sanilac County, Michigan.</description>
</item>
<item>
<title>Doral Renewables Secures Nearly $900 Million of Financing Commitments for Construction of Cold Creek Solar + Storage Project</title>
<link>https://6ix.com/company/banco-santander-sa/news/doral-renewables-secures-nearly-dollar900-million-of-financing-commitments-for-construction-of-cold-creek-solar-storage-project-1</link>
<guid isPermaLink="true">https://6ix.com/company/banco-santander-sa/news/doral-renewables-secures-nearly-dollar900-million-of-financing-commitments-for-construction-of-cold-creek-solar-storage-project-1</guid>
<pubDate>Tue, 24 Mar 2026 11:30:00 GMT</pubDate>
<description>Doral Renewables LLC ("Doral"), a leading, U.S. utility-scale solar and battery storage developer and independent power producer, announced today the successful financial close for the Cold Creek Solar + Storage project in Schleicher and Tom Green Counties in Texas.</description>
</item>
<item>
<title>Press release: Availability of the Q1 2026 aide-mémoire</title>
<link>https://6ix.com/company/banco-santander-sa/news/press-release-availability-of-the-q1-2026-aide-memoire-2</link>
<guid isPermaLink="true">https://6ix.com/company/banco-santander-sa/news/press-release-availability-of-the-q1-2026-aide-memoire-2</guid>
<pubDate>Tue, 24 Mar 2026 06:30:00 GMT</pubDate>
<description>Availability of the Q1 2026 aide-mémoire Paris, France – March 24, 2026. Sanofi announced today the availability of its Q1 2026 aide-mémoire on the "Investors" page of the company's website: First quarter 2026 results (sanofi.com) Prepared each quarter, this document is intented to support financial modelling of the quarterly results. It covers non-comparable items, foreign currency impact, and share count. Sanofi's Q1 2026 results will be published on April 23, 2026. About Sanofi Sanofi is an R</description>
</item>
<item>
<title>Press Release: Sanofi and Regeneron’s Dupixent approved in Japan as the first targeted medicine to treat adults with bullous pemphigoid</title>
<link>https://6ix.com/company/banco-santander-sa/news/press-release-sanofi-and-regenerons-dupixent-approved-in-japan-as-the-first-targeted-medicine-to-treat-adults-with-bullous-pemphigoid-3</link>
<guid isPermaLink="true">https://6ix.com/company/banco-santander-sa/news/press-release-sanofi-and-regenerons-dupixent-approved-in-japan-as-the-first-targeted-medicine-to-treat-adults-with-bullous-pemphigoid-3</guid>
<pubDate>Tue, 24 Mar 2026 06:00:00 GMT</pubDate>
<description>Sanofi and Regeneron’s Dupixent approved in Japan as the first targeted medicine to treat adults with bullous pemphigoid Approval in moderate-to-severe patients was based on pivotal study results showing over four times more Dupixent patients experienced sustained disease remission through Week 36 compared with placeboBP is a chronic, relapsing skin disease with underlying type 2 inflammation characterized by intense itch alongside painful blisters and other lesionsBP is the seventh approved ind</description>
</item>
<item>
<title>Anew Climate Joins Carbon Measures to Advance Global Carbon Accounting Standards and Policies Supporting Market-Based Solutions</title>
<link>https://6ix.com/company/banco-santander-sa/news/anew-climate-joins-carbon-measures-to-advance-global-carbon-accounting-standards-and-policies-supporting-market-based-solutions</link>
<guid isPermaLink="true">https://6ix.com/company/banco-santander-sa/news/anew-climate-joins-carbon-measures-to-advance-global-carbon-accounting-standards-and-policies-supporting-market-based-solutions</guid>
<pubDate>Mon, 23 Mar 2026 13:00:00 GMT</pubDate>
<description>HOUSTON, TX / ACCESS Newswire / March 23, 2026 / Anew Climate, a global leader in low-carbon fuels and climate solutions, today announced it has joined Carbon Measures, a cross-industry coalition working to develop a new global carbon accounting framework ...</description>
</item>
<item>
<title>Tudor Abandons Appeal of the BC Chief Gold Commissioner's Decision Pertaining to Seabridge Gold's KSM's Mitchell Treaty Tunnels (MTT)</title>
<link>https://6ix.com/company/banco-santander-sa/news/tudor-abandons-appeal-of-the-bc-chief-gold-commissioners-decision-pertaining-to-seabridge-golds-ksms-mitchell-treaty-tunnels-mtt-3</link>
<guid isPermaLink="true">https://6ix.com/company/banco-santander-sa/news/tudor-abandons-appeal-of-the-bc-chief-gold-commissioners-decision-pertaining-to-seabridge-golds-ksms-mitchell-treaty-tunnels-mtt-3</guid>
<pubDate>Thu, 19 Mar 2026 11:30:00 GMT</pubDate>
<description>Toronto, Ontario--(Newsfile Corp. - March 19, 2026) - Seabridge Gold Inc. (TSX: SEA) (NYSE: SA) ("Seabridge" or the "Company") announced today that Tudor Gold Corp. ("Tudor") has filed a Notice of Abandonment of Appeal with the Supreme Court of British Columbia, thereby abandoning its appeal of the Chief Gold Commissioner's (CGC) decision relating to her authority to hear an application challenging KSM's Mitchell Treaty Tunnels (MTT). The CGC's decision, issued on May 28, 2025, declined...</description>
</item>
<item>
<title>Press Release: Sanofi’s venglustat earns Breakthrough Therapy designation in the US for type 3 Gaucher disease</title>
<link>https://6ix.com/company/banco-santander-sa/news/press-release-sanofis-venglustat-earns-breakthrough-therapy-designation-in-the-us-for-type-3-gaucher-disease-2</link>
<guid isPermaLink="true">https://6ix.com/company/banco-santander-sa/news/press-release-sanofis-venglustat-earns-breakthrough-therapy-designation-in-the-us-for-type-3-gaucher-disease-2</guid>
<pubDate>Wed, 18 Mar 2026 06:00:00 GMT</pubDate>
<description>Sanofi’s venglustat earns Breakthrough Therapy designation in the US for type 3 Gaucher disease Paris, March 18, 2026. The US Food and Drug Administration (FDA) has granted Breakthrough Therapy designation to venglustat, a novel, investigational oral glucosylceramide synthase inhibitor (GCSi), for the treatment of neurological manifestations of type 3 Gaucher disease (GD3), a rare lysosomal storage disorder. The designation is based on data from the LEAP2MONO phase 3 study (clinical study identi</description>
</item>
<item>
<title>rPlus Energies Secures Financing Commitments for 400-Megawatt Blacks Creek Energy Center</title>
<link>https://6ix.com/company/banco-santander-sa/news/rplus-energies-secures-financing-commitments-for-400-megawatt-blacks-creek-energy-center</link>
<guid isPermaLink="true">https://6ix.com/company/banco-santander-sa/news/rplus-energies-secures-financing-commitments-for-400-megawatt-blacks-creek-energy-center</guid>
<pubDate>Tue, 17 Mar 2026 11:00:00 GMT</pubDate>
<description>The Idaho‑Based Energy Generation Project Advances Toward Construction as rPlus Energies Scales Across the American WestSALT LAKE CITY, March 17, 2026 (GLOBE NEWSWIRE) -- rPlus Energies announced today that it has secured over $650 million in debt facilities, along with tax equity financing commitments, for Blacks Creek Energy Center, a 400‑megawatt (MW) ac / 520 MWdc solar facility located in Ada County, Idaho. The financing package includes a debt financing facility, led by Santander Corporate</description>
</item>
<item>
<title>Arevon Closes $920 Million in Financing for its 1,200 Megawatt-Hour Nighthawk Energy Storage Project in California</title>
<link>https://6ix.com/company/banco-santander-sa/news/arevon-closes-dollar920-million-in-financing-for-its-1200-megawatt-hour-nighthawk-energy-storage-project-in-california-1</link>
<guid isPermaLink="true">https://6ix.com/company/banco-santander-sa/news/arevon-closes-dollar920-million-in-financing-for-its-1200-megawatt-hour-nighthawk-energy-storage-project-in-california-1</guid>
<pubDate>Wed, 11 Mar 2026 12:00:00 GMT</pubDate>
<description>Arevon Energy, Inc., a leading American energy developer, owner, and operator, today announced it has successfully closed a $920 million financing package for its 300 megawatt (MW)/1,200 megawatt-hour (MWh) Nighthawk Energy Storage Project, currently under construction in Poway, California.</description>
</item>
</channel>
</rss>